Elbit Medical Imaging Ltd
This article was originally published in The Gray Sheet
Executive Summary
Israeli firm decides to scuttle a proposed merger with publicly traded subsidiary Elscint Ltd. As outlined in a Feb. 18 proposal, Elbit was to acquire the roughly 43% (7 mil. shares) of Elscint that it did not already own at $14 per share, or $98.2 mil. (1"The Gray Sheet" Feb. 22, p. 12). Elscint received a letter from a committee of Elbit independent directors stating that the proposed business combination "would not be in the best interests of shareholders." Elscint says its board "is in the late stages of a long-term process of evaluating various alternatives to increase shareholder value"
You may also be interested in...
Elbit/Elscint
Combination of Elbit Medical Imaging Ltd. with its publicly traded Elscint Ltd. subsidiary is outlined in a $14-per-share acquisition proposal announced Feb. 18. Under the terms of the $98.2 mil. deal, Elbit will acquire the roughly 7 mil. Elscint shares not currently owned by Elbit, or roughly 43% of the company. The $14-per-share price represents a 21% premium over Elscint's Feb. 17 closing price of 11-9/16. Haifa, Israel-based Elscint, developer of computer-based medical imaging systems, divested its nuclear medicine and magnetic resonance medical imaging businesses to General Electric's GE Medical Sytems division for $100 mil. in November. Sold simultaneously for $269.5 mil. was Elscint's computed tomography division, which went to Picker International, a subsidiary of U.K.-based General Electric Company, plc
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.